Drug intelligence / Profile preview

MK-8723

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Intravenous

Overview

MK-8723 is an investigational small molecule drug developed by Merck Sharp & Dohme (Merck & Co) as an intravenously administered treatment for idiopathic thrombocytopenic purpura (ITP), also known as immune thrombocytopenia. It was studied in a phase 1 clinical trial to assess its safety, pharmacokinetics, and pharmacodynamics in both healthy adults and patients with chronic ITP. The drug belongs to the antithrombotic class, but its precise molecular target and mechanism of action have not been publicly disclosed. Development has not progressed beyond early clinical trials[1][2][4].

Beyond the preview

Go deeper on MK-8723.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-8723.

Explore the full profile